Wade T Iams1, Hui Yu2, Yu Shyr3, Tejas Patil4, Leora Horn5, Caroline McCoach6, Karen Kelly7, Robert C Doebele4, D Ross Camidge8. 1. Division of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL. 2. Department of Internal Medicine, University of New Mexico, Albuquerque, NM. 3. Department of Statistics, Vanderbilt-Ingram Cancer Center, Nashville, TN. 4. Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, CO. 5. Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN. 6. Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA. 7. Department of Medical Oncology, University of California, Davis, Sacramento, CA. 8. Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, CO. Electronic address: ross.camidge@ucdenver.edu.
Abstract
BACKGROUND: Unsuccessful KRAS-specific treatment approaches in non-small-cell lung cancer (NSCLC) might reflect underlying disease heterogeneity. We sought to define clinical "syndromes" within advanced KRAS mutant NSCLC to improve future clinical trials and create a clinical framework for future molecular development. PATIENTS AND METHODS: To test a series of a priori hypotheses regarding KRAS-mutant NSCLC clinical syndromes, we conducted a multi-institutional retrospective medical record review. Survival probabilities were estimated using the Kaplan-Meier model. Between-group differences were assessed using the log-rank test. Multivariate Cox regression analyses and Wilcoxon rank sum testing were used to assess progression-free survival and overall survival (OS) differences. RESULTS: Among 218 patients with advanced KRAS-mutant NSCLC, OS and progression-free survival with first-line chemotherapy did not differ by intrathoracic versus extrathoracic spread, smoking intensity, or the specific KRAS mutation. Metastatic disease at diagnosis resulted in significantly worse OS than recurrent, unresectable disease (median OS, 14.6 vs. 40.9 months; P = .001). Among the patients with metastatic disease at diagnosis, nonscalp, soft tissue metastases (syndrome X; 6% of cases; 95% confidence interval [CI], 2.5%-10.1%) signified a poor prognosis (median OS, 7.5 vs. 15.9 months for the controls; P = .021). The response to first-line chemotherapy (syndrome Y; 41% of cases; 95% CI, 32.3%-50.6%) signified a good prognosis (median OS, 26.7 vs. 11.9 months; P = .002). The overlap between these 2 syndromes was minimal (2 of 111). Multivariate analysis confirmed these observations. The hazard ratio for death for syndromes X and Y was 2.64 (95% CI, 1.13-6.14) and 0.45 (95% CI, 0.28-0.76), respectively. CONCLUSION: Chemotherapy-responsive disease and nonscalp, soft tissue spread might represent distinct clinical syndromes within KRAS-mutant NSCLC. The molecular biology underlying this heterogeneity warrants future studies.
BACKGROUND: Unsuccessful KRAS-specific treatment approaches in non-small-cell lung cancer (NSCLC) might reflect underlying disease heterogeneity. We sought to define clinical "syndromes" within advanced KRAS mutant NSCLC to improve future clinical trials and create a clinical framework for future molecular development. PATIENTS AND METHODS: To test a series of a priori hypotheses regarding KRAS-mutant NSCLC clinical syndromes, we conducted a multi-institutional retrospective medical record review. Survival probabilities were estimated using the Kaplan-Meier model. Between-group differences were assessed using the log-rank test. Multivariate Cox regression analyses and Wilcoxon rank sum testing were used to assess progression-free survival and overall survival (OS) differences. RESULTS: Among 218 patients with advanced KRAS-mutant NSCLC, OS and progression-free survival with first-line chemotherapy did not differ by intrathoracic versus extrathoracic spread, smoking intensity, or the specific KRAS mutation. Metastatic disease at diagnosis resulted in significantly worse OS than recurrent, unresectable disease (median OS, 14.6 vs. 40.9 months; P = .001). Among the patients with metastatic disease at diagnosis, nonscalp, soft tissue metastases (syndrome X; 6% of cases; 95% confidence interval [CI], 2.5%-10.1%) signified a poor prognosis (median OS, 7.5 vs. 15.9 months for the controls; P = .021). The response to first-line chemotherapy (syndrome Y; 41% of cases; 95% CI, 32.3%-50.6%) signified a good prognosis (median OS, 26.7 vs. 11.9 months; P = .002). The overlap between these 2 syndromes was minimal (2 of 111). Multivariate analysis confirmed these observations. The hazard ratio for death for syndromes X and Y was 2.64 (95% CI, 1.13-6.14) and 0.45 (95% CI, 0.28-0.76), respectively. CONCLUSION: Chemotherapy-responsive disease and nonscalp, soft tissue spread might represent distinct clinical syndromes within KRAS-mutant NSCLC. The molecular biology underlying this heterogeneity warrants future studies.
Authors: Diarmuid M Moran; Patricia B Trusk; Karen Pry; Keren Paz; David Sidransky; Sarah S Bacus Journal: Mol Cancer Ther Date: 2014-03-31 Impact factor: 6.261
Authors: Helena A Yu; Camelia S Sima; Matthew D Hellmann; Jarushka Naidoo; Natalie Busby; Katherine Rodriguez; Gregory J Riely; Mark G Kris Journal: Cancer Date: 2015-03-17 Impact factor: 6.860
Authors: Nathan T Ihle; Lauren A Byers; Edward S Kim; Pierre Saintigny; J Jack Lee; George R Blumenschein; Anne Tsao; Suyu Liu; Jill E Larsen; Jing Wang; Lixia Diao; Kevin R Coombes; Lu Chen; Shuxing Zhang; Mena F Abdelmelek; Ximing Tang; Vassiliki Papadimitrakopoulou; John D Minna; Scott M Lippman; Waun K Hong; Roy S Herbst; Ignacio I Wistuba; John V Heymach; Garth Powis Journal: J Natl Cancer Inst Date: 2012-01-13 Impact factor: 13.506
Authors: Paul K Paik; Melissa L Johnson; Sandra P D'Angelo; Camelia S Sima; Daphne Ang; Snjezana Dogan; Vincent A Miller; Marc Ladanyi; Mark G Kris; Gregory J Riely Journal: Cancer Date: 2012-05-17 Impact factor: 6.860